|
News for: |
|
You will land on a page at the National Library of Medicine where you can drill down to consumer info, research citations, product labelling, toxicology and more. FindingHealthOnline is the world's leading health-pharma search portal and decision engine. It helps you drill down to very detailed information without interference from commercial sites that now dominate Bing, Google, and Yahoo. Near the top of our pages, you will find a link to content that best matches your query.
|
|
|
FDA Approval Activities for this Drug…
Lamictal (lamotrigine) Tablets, SmithKline Beecham NDA 20-241/S-018 4/4/03 4/18/03 Lamictal (lamotrigine) Tablets & Chewable Dispersible Tablets, GlaxoSmithKline NDA 20-241/S-017 & 20-764/S-011 6/20/03 7/6/03 7/8/03 Lamictal (lamotrigine) Tablets & Chewable Dispersible Tablets, 25, 100, 150 and 200mg & 2.5 and 25 mg, Glaxo Wellcome NDA 20-241/S-008 & 20-764/S-002 1/17/03 1/23/03 Lamictal (lamotrigine) Chewable Dispersible Tablets,Dear Health Professional Letter Glaxo Wellcome NDA 20-764 8/24/98 8/24/98 8/24/98 5/20/99 Lamictal Indications: This application provides bioequivalency data to support a new dosage form of lamotrigine, and clinical data to support a new indication for the use of lamotrigine, as compared to the already approved Lamictal Tablet. Specifically, the new indication is for the use of lamotrigine for adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients. Lamictal (lamotrigine) Tablets,Dear Health Professional Letter Glaxo Wellcome NDA 20-241/ S-002: 8/24/98 8/24/98 8/24/98 5/20/99 Lamictal Indications: This application (NDA 20-241/S-002), an efficacy supplement, incorporates by reference the clinical data contained in the Lamictal CD Chewable Tablet application (NDA 20-764) so that the approved compressed tablet formulation can gain the new indication, as well. This cross-reference also allows for the development of one label for both lamotrigine products. Lamictal (lamotrigine) Tablets& Lamictal (lamotrigine) Chewable Dispersible Tablets,Dear Health Professional Letter Glaxo Wellcome NDA 20-241/S-003 & NDA 20-764/S-001 12/14/98 12/15/98 12/15/98 6/30/99 Lamictal Indications: These efficacy supplements provide for the use of Lamictal as conversion to monotherapy in adults with partial seizures who are receiving treatment with a single enzyme-inducing antiepileptic drug (EIAED). Lamictal Tablets and Lamictal Chewable Dispersible Tablets , Glaxo Wellcome NDA 20-241/S-011 & NDA 20-764/S-005: 5/25/01 5/29/01 Lamictal Indication: Application provides for: clinical data in support of a labeling revision to update the Geriatric Use subsection of the Lamictal package insert. Lamictal (lamotrigine) Tablets, SmithKline Beecham NDA 20-241/S-018 4/4/03 4/18/03 Lamictal (lamotrigine) Tablets & Chewable Dispersible Tablets, GlaxoSmithKline NDA 20-241/S-017 & 20-764/S-011 6/20/03 7/6/03 7/8/03 Lamictal (lamotrigine) Tablets & Chewable Dispersible Tablets, 25, 100, 150 and 200mg & 2.5 and 25 mg, Glaxo Wellcome NDA 20-241/S-008 & 20-764/S-002 1/17/03 1/23/03 Lamictal (lamotrigine) Chewable Dispersible Tablets,Dear Health Professional Letter Glaxo Wellcome NDA 20-764 8/24/98 8/24/98 8/24/98 5/20/99 Lamictal Indications: This application provides bioequivalency data to support a new dosage form of lamotrigine, and clinical data to support a new indication for the use of lamotrigine, as compared to the already approved Lamictal Tablet. Specifically, the new indication is for the use of lamotrigine for adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients. Lamictal (lamotrigine) Tablets,Dear Health Professional Letter Glaxo Wellcome NDA 20-241/ S-002: 8/24/98 8/24/98 8/24/98 5/20/99 Lamictal Indications: This application (NDA 20-241/S-002), an efficacy supplement, incorporates by reference the clinical data contained in the Lamictal CD Chewable Tablet application (NDA 20-764) so that the approved compressed tablet formulation can gain the new indication, as well. This cross-reference also allows for the development of one label for both lamotrigine products. Lamictal (lamotrigine) Tablets& Lamictal (lamotrigine) Chewable Dispersible Tablets,Dear Health Professional Letter Glaxo Wellcome NDA 20-241/S-003 & NDA 20-764/S-001 12/14/98 12/15/98 12/15/98 6/30/99 Lamictal Indications: These efficacy supplements provide for the use of Lamictal as conversion to monotherapy in adults with partial seizures who are receiving treatment with a single enzyme-inducing antiepileptic drug (EIAED). Lamictal Tablets and Lamictal Chewable Dispersible Tablets , Glaxo Wellcome NDA 20-241/S-011 & NDA 20-764/S-005: 5/25/01 5/29/01 Lamictal Indication: Application provides for: clinical data in support of a labeling revision to update the Geriatric Use subsection of the Lamictal package insert. Lamictal (lamotrigine) Tablets & Chewable Dispersible Tablets, GlaxoSmithKline | Lamictal (lamotrigine) Tablets, SmithKlineBeecham, Labeling Revision | Lamictal (lamotrigine) Chewable Dispersible Tablets, SmithKlineBeecham, Labeling Revision | Lamotigine Tablets, Genpharm Inc., Tentative Approval | Lamotrigine Tablets, Teva Pharma, Approval | Lamotrigine Tablets, Genpharm Inc., Tentative Approval | Lamotrigine Tablets, Roxane Labs, Tentative Approval | Lamotrigine Tablets, TEVA Pharmaceuticals, Approval | Lamictal (lamotrigine) Tablets, GlaxoSmithKline, New or Modified Indication | Lamictal (lamotrigine) Chewable Dispensible Tablets, GlaxoSmithKline, New or Modified Indication | Lamictal (lamotrigine) Tablets, GlaxoSmithKline, Labeling Revision | Lamictal (lamotrigine) Chewable Dispensible Tablets, GlaxoSmithKline, , Labeling Revision
|